Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective

[1]  Jinseub Hwang,et al.  Lifetime survival and medical costs of lung cancer: a semi-parametric estimation from South Korea , 2020, BMC cancer.

[2]  J. Penrod,et al.  Costs and Cost Drivers Associated with Non-Small-Cell Lung Cancer Patients Who Received Two or More Lines of Therapy in Europe , 2020, ClinicoEconomics and outcomes research : CEOR.

[3]  J. Darbà,et al.  The cost of lost productivity due to premature lung cancer-related mortality: results from Spain over a 10-year period , 2019, BMC Cancer.

[4]  W. Evans,et al.  Cost-of-illness study for non-small-cell lung cancer using real-world data. , 2019, Current oncology.

[5]  K. Syrigos,et al.  End-of-Life Health-Care Cost of Patients With Lung Cancer: A Retrospective Study , 2019, Health services research and managerial epidemiology.

[6]  R. Wood,et al.  Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage , 2019, BMC Cancer.

[7]  J. Kwon,et al.  Economic burden of lung cancer: A retrospective cohort study in South Korea, 2002-2015 , 2019, PloS one.

[8]  F. Barlesi,et al.  Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS). , 2018, Lung cancer.

[9]  J. Schellens,et al.  Changing costs of metastatic non small cell lung cancer in the Netherlands. , 2017, Lung cancer.

[10]  T. Hu,et al.  Economic Burden for Lung Cancer Survivors in Urban China , 2017, International journal of environmental research and public health.

[11]  G. Fasola,et al.  Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study , 2017, Journal of Cancer Research and Clinical Oncology.

[12]  B. K. Matin,et al.  Estimating the Economic Burden of Lung Cancer in Iran , 2016, Asian Pacific journal of cancer prevention : APJCP.

[13]  Bayram Şahin,et al.  Cost-effectiveness analysis of pemetrexed and gemcitabine treatment for advanced nonsmall cell lung cancer in Turkey. , 2016, Turkish journal of medical sciences.

[14]  Ahmedin Jemal,et al.  Global Cancer Incidence and Mortality Rates and Trends—An Update , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[15]  E. Panagopoulou,et al.  Estimating the direct and indirect costs of lung cancer: a prospective analysis in a Greek University Pulmonary Department. , 2015, Journal of thoracic disease.

[16]  Jacek Jassem,et al.  Caring for relatives with lung cancer in Europe: an evaluation of caregivers’ experience , 2015, Quality of Life Research.

[17]  Julieta Corral,et al.  Estimation of lung cancer diagnosis and treatment costs based on a patient-level analysis in Catalonia (Spain) , 2015, BMC Health Services Research.

[18]  I. Soerjomataram,et al.  Measuring the societal burden of cancer: The cost of lost productivity due to premature cancer‐related mortality in Europe , 2015, International journal of cancer.

[19]  S. Karve,et al.  Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers , 2014, BMC Health Services Research.

[20]  J. Timsit,et al.  Intensive care in patients with lung cancer: a multinational study. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  L. Sharp,et al.  The cost of premature cancer-related mortality: a review and assessment of the evidence , 2014, Expert review of pharmacoeconomics & outcomes research.

[22]  Yi-Lin Wu,et al.  Estimating the lifelong health impact and financial burdens of different types of lung cancer , 2013, BMC Cancer.

[23]  A. Gray,et al.  Economic burden of cancer across the European Union: a population-based cost analysis. , 2013, The Lancet. Oncology.

[24]  S. Vinod,et al.  Cost analysis of lung cancer management in South Western Sydney , 2012, Journal of medical imaging and radiation oncology.

[25]  L. Landi,et al.  Targeted therapies: Front-line therapy in lung cancer with mutations in EGFR , 2011, Nature Reviews Clinical Oncology.

[26]  D. Isla,et al.  Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel , 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[27]  Eric J Feuer,et al.  Projections of the cost of cancer care in the United States: 2010-2020. , 2011, Journal of the National Cancer Institute.

[28]  Audie A Atienza,et al.  Economic burden for informal caregivers of lung and colorectal cancer patients. , 2010, The oncologist.

[29]  F. Schramel,et al.  Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in The Netherlands. , 2009, Lung cancer.

[30]  K. Fox,et al.  Metastatic non-small cell lung cancer: costs associated with disease progression. , 2008, The American journal of managed care.

[31]  D. Hailey,et al.  The cost of lung cancer in Alberta. , 2007, Canadian respiratory journal.

[32]  Lee Bowman,et al.  The economic burden of lung cancer and the associated costs of treatment failure in the United States. , 2005, Lung cancer.

[33]  F. Shepherd,et al.  Economic issues in lung cancer: a review. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Huisman.  The Netherlands , 1996, The Lancet.

[35]  Jing Shi,et al.  Health Resource Utilization in Patients with Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy in China , 2015, Clinical Drug Investigation.

[36]  Jacques Ferlay,et al.  GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012 , 2013 .

[37]  C. Combescure,et al.  Cost of Lung Cancer , 2012, PharmacoEconomics.

[38]  C. Earle,et al.  Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[39]  A. Wertheimer,et al.  The economic burden. , 2010, Advances in experimental medicine and biology.

[40]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[41]  F. Sloan.  Valuing health care : costs, benefits, and effectiveness of pharmaceuticals and other medical technologies , 1995 .